Bifidobacterium animalis subsp. lactis (BB-12, HN019, DN-173 010)
Bifidobacterium animalis subsp. lactis is one of the most- studied probiotic bacteria in the world — the strain that put Danone's Activia yoghurt on supermarket shelves and the bifidobacterium most commonly added to UK probiotic capsules. The "lactis" subspecies (distinct from B. animalis subsp. animalis, which is more common in animals than humans) is found in your gut and in fermented dairy products. There are NO UK-authorised generic health claims for B. animalis lactis, although brand-specific transit-time claims (Activia / Bifidus Regularis) operate under a separate regulatory framework. Three trial-grade strains dominate the published literature (over 200 RCTs combined across four decades): 1. <strong>BB-12</strong> (Chr Hansen, Denmark) — the most- cited strain; used in Activia variants and many capsule supplements; trial evidence for antibiotic-associated diarrhoea prevention (in combination with L. rhamnosus GG), paediatric acute gastroenteritis, and general gut-flora support. 2. <strong>HN019</strong> (Fonterra / DuPont, New Zealand) — Cheng 2021 review (PMID 34970580) covers transit-time improvement in functional constipation, intestinal-barrier function, and immune-response support in elderly adults. Available in UK Optibac and ProVen brands. 3. <strong>DN-173 010</strong> (Danone, France) — the original Activia / Bifidus Regularis strain with multiple RCTs supporting reduced colon transit time in women with mild constipation. Delivered as fermented dairy in UK supermarkets. Strain identification matters: trial-evidenced health claims apply only when the specific strain is on the label at the trial-evidenced dose. "Bifidobacterium animalis lactis" without a strain identifier (BB-12, HN019, DN-173 010) does not carry the strain-specific evidence. Talk to your GP if you have a specific clinical indication; UK NICE pathways do not currently include B. animalis lactis for any indication.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Probiotic
- Typical daily dose
- Yoghurt-fortified: 100-200 g/day. Capsule: 10⁹-10¹⁰ CFU/day. Trial-evidence dose for AAD prevention (BB-12 + LGG combination): 10⁹-10¹⁰ CFU each strain, twice daily during antibiotic course + 1-2 weeks after.
- Top use evidence
- Moderate
On this page
What it is
Bifidobacterium animalis is a Gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus. Two subspecies are recognised:
- B. animalis subsp. animalis — the original isolated form (1969 from rat faeces). Less common in human gut microbiota.
- B. animalis subsp. lactis — isolated from fermented dairy products. The form found in commercial human probiotic products. Camden's entry focuses on this subspecies.
Three trial-grade strains dominate the published literature:
- BB-12 (Chr. Hansen, Denmark) — first commercialised in 1985, deposited in DSMZ as DSM 15954. Used in Activia fermented dairy; Yakult LC-1; many capsule supplements. Most-cited strain in the bifidobacterium clinical-trial literature with 200+ trials over four decades.
- HN019 (Fonterra / DuPont, New Zealand) — DR10 / DSM 19657. Second most-cited strain. Substantial elderly-immune-function and infant-immune trial body. Marketed in UK Optibac, ProVen, Yakult Lactobacillus + Bifidobacterium products.
- DN-173 010 (Danone, France) — the original Activia / Bifidus Regularis branded strain. CNCM I-2494. Multiple RCTs supporting reduced colon transit time as the basis for the Activia constipation-relief framing.
UK consumer products span:
- Yoghurt-fortified delivery: Activia (Danone, DN-173 010), Yakult Plus (LC-1 / BB-12 combinations), supermarket own-brand fermented dairy with B. lactis.
- Capsule supplements: Optibac Bifidobacteria & Fibre (HN019), ProVen Probiotics (HN019), Bio-Kult (multi-strain including BB-12 variants), Symprove (multi-strain liquid).
- Powder / sachet formats: Maypro / Wakunaga liquid live cultures.
Distinct from the closely-related Bifidobacterium longum (Camden bifidobacterium-longum — different species, separate trial evidence) and from the next-generation Akkermansia muciniphila (Camden akkermansia-muciniphila — different phylum, mucin-degrading rather than carbohydrate-fermenting).
At a glance
- Most-trialled bifidobacterium strain in human research. Three trial-grade strains: BB-12 (Chr. Hansen — Activia + capsules), HN019 (Fonterra/DuPont — Optibac), DN-173 010 (Danone Activia / Bifidus Regularis).
- Strain-specific evidence: BB-12 antibiotic-associated diarrhoea + paediatric gastroenteritis; HN019 transit time + elderly immune function (Cheng 2021 review PMID 34970580); DN-173 010 transit time in women with mild constipation.
- Distinct from B. animalis subsp. animalis (less common in humans) and from B. longum (Camden bifidobacterium-longum — different species).
- NO UK-authorised generic Article 13.1 health claims for B. animalis lactis. Brand-specific transit-time wording (Activia / Bifidus Regularis) operates under EU Reg 432/2012.
- Strain identification is load-bearing: "Bifidobacterium animalis lactis" without trial-grade strain identifier (BB-12 / HN019 / DN-173 010) does NOT carry the strain-specific clinical evidence.
- Yoghurt-substrate delivery (Activia, supermarket fermented dairy) vs capsule delivery (Optibac, ProVen, Bio-Kult) — both valid; capsule delivers higher CFU per serving; yoghurt delivers within food-matrix context.
What people use it for
Adults with chronic constipation or sluggish bowel transit
DN-173 010 (Activia) has multiple RCTs supporting reduced transit time and improved stool frequency. UK NICE CKS Constipation pathway is lifestyle (fluid, fibre, exercise) + osmotic / stimulant laxatives + (where indicated) prucalopride / linaclotide. Probiotic adjunct as a lifestyle measure is reasonable; not a primary clinical intervention. [2]
Some evidenceModerateAdults preventing antibiotic-associated diarrhoea (AAD)
BB-12 + L. rhamnosus GG combinations have Cochrane review-supported AAD prevention. Take alongside antibiotic course; continue 1-2 weeks after antibiotic completion. UK NICE CKS Diarrhoea pathway includes consideration of probiotic adjunct. [3]
Some evidenceModerateAdults with general gut-health / microbiome-diversity goals
Generic probiotic biomass + transit-time framing. UK NICE pathways for IBS use specific interventions (low-FODMAP, antispasmodics, antidepressants for IBS-D). Probiotic strain-specific evidence varies by indication; B. animalis lactis is among the better-evidenced bifidobacterium strains. [5]
Some evidenceLimitedElderly adults supporting immune function
HN019 has elderly-immune-function trial body (Gill 2001, Arunachalam 2000) — increased phagocytic + NK-cell activity. Effect sizes modest. Established in over-65s + immune-supportive product positioning.
Some evidenceLimitedPregnant or breastfeeding women
B. animalis lactis is widely consumed via yoghurt-fortified products in pregnancy without obvious safety signals. Capsule supplementation generally fine. Specific strain-claim wording does not attach to pregnancy / lactation — talk to midwife if concerned. [8]
Some evidenceLimitedSeverely immunocompromised adults
Caution as with all live probiotic strains in severe immunocompromise. Talk to clinical team. Pasteurised products (Akkermansia framework) — see Camden akkermansia-muciniphila for the pasteurised alternative pathway.
Some evidenceLimited
How it works
Carbohydrate fermentation + SCFA production. B. animalis lactis ferments dietary oligosaccharides (FOS, GOS, inulin) into short-chain fatty acids (acetate, lactate, formate). SCFAs are the colonic-energy substrates and signal cellular receptors (FFAR2, FFAR3) that modulate gut motility, glucose metabolism, and immune signalling.
Colonic transit-time reduction. DN-173 010 (Activia strain) has multiple RCTs supporting reduced colon transit time and improved stool frequency. Mechanism: colonic motility-stimulation via SCFA / vagal afferent signalling; bile-acid metabolism modulation; gut-microbiota composition shift toward higher Bifidobacterium / lactobacillus proportions.
Immune-system modulation. HN019 in elderly trial populations increased phagocytic activity of polymorphonuclear cells + natural killer cell tumoricidal activity (Gill 2001, Arunachalam 2000). Mechanism via gut-immune axis Peyer's patch + mesenteric lymph node interactions.
Adhesion to gut epithelium. BB-12 has documented capacity to adhere to human intestinal mucus + epithelial cells (vs many probiotic strains that pass through without adhesion). Adhesion supports transient gut-residence + competitive exclusion of pathogens.
Antibiotic-associated diarrhoea (AAD) prevention. BB-12 + L. rhamnosus GG combinations show strain-specific AAD prevention in paediatric and adult RCTs — Cochrane systematic review supportive.
Acute gastroenteritis support. Cochrane review of probiotics for acute paediatric gastroenteritis showed reduced diarrhoea duration with specific strains including B. animalis lactis BB-12 (alongside L. rhamnosus GG and S. boulardii).
Common myths
Myth""All bifidobacterium products work the same.""
RealityStrain-specific evidence applies. BB-12, HN019, DN-173 010 each have their own clinical-indication evidence base. B. animalis lactis as a species is well-evidenced; B. animalis subsp. animalis (the original isolation) is less common in human use. Generic "bifidobacterium" without strain identification carries no specific clinical claim.
Myth""Activia cures constipation.""
RealityDN-173 010 (Activia / Bifidus Regularis) has trial-supported reduced transit time and improved stool frequency. NOT a cure. UK NICE CKS Constipation pathway is lifestyle (fluid, fibre, exercise) + laxatives + (where indicated) prokinetic medication; Activia is a lifestyle adjunct. [2]
Myth""Yoghurt is enough — I don't need a probiotic capsule.""
RealityBoth forms have value in different contexts. Yoghurt delivers within food matrix + lower CFU per serving (typically 10⁷-10⁸ CFU/100g). Capsule supplements deliver higher CFU (typically 10⁹-10¹⁰ CFU/dose) and specific trial-grade strains. For specific clinical indications (AAD prevention, IBS), capsule is more trial-comparable; for general microbiome-supportive intake, yoghurt works.
What people say online
B. animalis lactis discourse on TikTok and Reddit clusters around four narratives: "Activia transit-time benefit" (real but specific-strain-evidenced); "BB-12 for antibiotic diarrhoea" (Cochrane-supported); generic-bifidobacterium vs strain-specific marketing confusion; and "probiotic capsules are better than yoghurt" (depends on indication + dose). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #gutgesundheit + r/IBS + r/Constipationhigh visibility
Claim: Activia really works for constipation
Reality check: Strain-specific evidence does support DN-173 010 (the Activia / Bifidus Regularis strain) for reducing intestinal transit time in women with mild constipation; multiple Danone-sponsored RCTs underpin the Activia marketing. UK NICE CKS Constipation pathway uses dietary fibre + osmotic / stimulant laxatives + lifestyle as first-line; Activia / B. animalis lactis is an adjunct, not a UK NICE-recommended intervention. For chronic constipation talk to your GP.
- TikTok #guthealth + r/Antibioticshigh visibility
Claim: BB-12 prevents antibiotic diarrhoea
Reality check: Trial evidence supports the BB-12 + L. rhamnosus GG combination (Cochrane meta-analyses) for AAD prevention in paediatric and adult populations. UK NICE CKS Diarrhoea pathway acknowledges probiotic adjunct. Start probiotic at the same time as antibiotic; separate by 2-3 hours within each day; continue 1-2 weeks after antibiotic completion.
- TikTok + r/Probioticsmedium visibility
Claim: Capsules are always better than yoghurt for probiotics
Reality check: Depends on indication and dose. Capsules deliver higher CFU per serving (10⁹-10¹⁰ vs ~10⁸ in 100 g yoghurt) and can deliver specific trial-grade strains at the trial-evidenced dose. Yoghurt-fortified delivery (Activia, supermarket fermented dairy) is fine for general microbiome support and dietary fibre / protein context. For specific clinical indications (AAD prevention, paediatric AGE), capsule with trial-grade strain at trial-evidenced CFU is the evidence-based route.
- TikTok #probiotics + supplement-industry Redditmedium visibility
Claim: Any bifidobacterium probiotic delivers the same benefits
Reality check: Inaccurate. Strain-specific clinical claims apply only when the specific trial-grade strain (BB-12, HN019, DN-173 010) is on the label at the trial-evidenced dose. "Bifidobacterium animalis lactis" without strain identifier (or "bifidobacterium" without species or strain) does NOT carry the strain-specific evidence. Read the label.
Where the conversation lives
- TikTok hashtags: #activia, #probiotics, #guthealth, #constipation, #microbiome, #antibioticdiarrhea
- Reddit subs: r/Probiotics, r/IBS, r/Constipation, r/Antibiotics, r/microbiome
- Forums: Examine.com (paid evidence comparator), Optibac community sites
Questions people are searching
- Yoghurt or capsule for B. animalis?
- Should I take B. animalis with antibiotics?
- Can I take B. animalis in pregnancy?
- Activia vs Optibac vs supermarket yoghurt — which?
- Does the brand or the strain matter?
Who drives the discourse: The discourse is driven by four creator classes: gut-health / functional-medicine creators (the Activia transit-time framing — generally accurate); paediatric / women's-health creators (the AAD prevention + paediatric AGE framings — Cochrane-supported); supplement-comparison creators (the strain-specificity vs generic-bifidobacterium nuance — accurate when surfaced); and brand-marketing creators (sometimes blurring strain-specificity in favour of "all bifidobacterium is the same"). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Bifidobacterium animalis subsp. lactis (BB-12, HN019, DN-173 010). Each answer is editorial and links to its evidence in the Sources list below.
BB-12 or HN019 — which?
Different clinical-indication trial bodies. BB-12 has the largest trial base + AAD prevention + paediatric gastroenteritis evidence. HN019 has elderly-immune-function evidence. DN-173 010 has the constipation-transit-time claim. Choose based on indication.
Yoghurt or capsule probiotic?
Yoghurt-fortified delivery (Activia DN-173 010, similar) works for lifestyle-tier microbiome-supportive intake. Capsule supplements (BB-12, HN019, multi-strain Bio-Kult, Optibac) deliver higher CFU + specific trial-grade strains for specific clinical indications.
Should I take B. animalis with antibiotics?
Yes — BB-12 + L. rhamnosus GG combination is Cochrane-supported for antibiotic-associated diarrhoea prevention. Take a couple of hours after each antibiotic dose; continue 1-2 weeks after antibiotic completion. UK NICE CKS Diarrhoea pathway considers probiotic adjunct. [3]
Can I take B. animalis in pregnancy?
Yes — widely consumed via yoghurt-fortified products in pregnancy without obvious safety signals. Capsule supplementation generally fine. Talk to midwife if concerned. [8]
UK regulatory landscape
UK regulatory tier: Food supplement
B. animalis lactis sits under the UK Food Supplements (England) Regulations 2003 (when sold as a capsule supplement) and standard food regulation (when sold in fermented dairy products). There is NO UK-authorised Article 13.1 generic health claim for B. animalis lactis; EFSA Article 13 generic-probiotic evaluations remain on hold. Brand-specific transit-time claims for DN-173 010 (Activia / Bifidus Regularis) operate under separate EU Reg 432/2012 strain-specific authorisation. B. animalis is NOT a novel food — long history of fermented-dairy use predates 15 May 1997.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing for diagnosed IBS, IBD, chronic constipation as treatment | |
| Marketing strain-specific clinical claims without strain identifier on label | |
| Marketing as antibiotic-associated diarrhoea prevention without disclosing combination requirement | |
| Cancer-prevention or anti-cancer marketing |
Permitted claims
NO generic UK Article 13.1 authorised health claim exists for B. animalis lactis. Brand-specific transit-time wording for DN-173 010 (Activia / Bifidus Regularis) operates under EU Reg 432/2012 strain-specific authorisation. Generic factual description (e.g., "B. animalis lactis is a bifidobacterium found in fermented dairy products and capsule supplements") is permitted.
Cross-jurisdiction note
B. animalis lactis is consumed globally — Activia (Danone) is sold across the EU, UK, US, and many other markets; capsule supplements with BB-12 / HN019 are available worldwide. The EU/UK regulatory framework is among the strictest on strain-specific health claims; US FDA DSHEA framework allows broader supplement marketing without the strain-specific gate.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Constipation / transit time
ModerateEvidencemoderateMultiple RCTs at DN-173 010 (Activia) and BB-12 supporting reduced transit time and improved stool frequency. UK NICE CKS Constipation pathway uses lifestyle + laxatives first-line; probiotic adjunct. [2]
Antibiotic-associated diarrhoea (AAD) prevention
ModerateEvidencemoderateBB-12 + L. rhamnosus GG combinations supportive in Cochrane review. UK NICE CKS Diarrhoea pathway considers probiotic adjunct. [3]
Paediatric acute gastroenteritis
ModerateEvidencemoderateCochrane probiotics-for-paediatric-gastroenteritis review supports specific strains including B. animalis lactis. UK NICE CKS Gastroenteritis pathway considers probiotic adjunct. [3]
Respiratory tract infection in elderly
LimitedEvidencelimitedHN019 trials (Gill 2001, Arunachalam 2000) showed reduced respiratory-infection incidence and improved immune-cell function in over-65s. Effect sizes modest.
IBS symptoms
LimitedEvidencelimitedSome IBS-symptom trials (multi-strain combinations including B. animalis lactis) supportive; UK NICE IBS pathway uses specific interventions. [5]
Clinical literature review
The B. animalis lactis literature is among the most-mature in probiotic research — over 200 RCTs across the BB-12, HN019, and DN-173 010 strains, covering paediatric acute gastroenteritis (Cochrane meta-analyses), antibiotic- associated diarrhoea prevention (BB-12 + LGG combination), transit-time improvement in functional constipation (HN019: Cheng 2021 review PMID 34970580; DN-173 010: multiple Danone-sponsored Activia trials), and respiratory / immune support in elderly populations (HN019). UK NICE pathways do NOT include B. animalis lactis specifically for any indication; UK NHS Eatwell Guide includes fermented dairy as routine dietary inclusion.
Key trials
Cheng J, Laitila A, Ouwehand AC · 2021 · Front Nutr · PMID 34970580
Finding: B. animalis subsp. lactis HN019 has documented effects on gut motility (reducing intestinal transit time and increasing bowel-movement frequency in functional constipation), intestinal barrier function (competing and excluding potential pathogens, maintaining tight- junction function), and immune defence toward pathogens. Effects in elderly populations (immunosenescence support). Mechanism via gut-brain-microbiota axis including serotonin signalling pathway and SCFAs from microbial fermentation. Authors conclude HN019 contributes to relieving gut-dysmotility-related disorders.
Relevance: The most comprehensive HN019 review for clinical translation. Covers transit-time + immune-function + barrier-function mechanisms across multiple RCTs. HN019 is a primary trial-grade strain alongside BB-12 and DN-173 010.
Systematic reviews
- pmid:34970580
Cheng 2021 Front Nutr — narrative review of B. animalis lactis HN019 documenting transit-time reduction, barrier function, and immune-defence effects across pre-clinical and clinical evidence.
Evidence quality summary
Strain-specific clinical effects (BB-12 / HN019 / DN-173 010) — MODERATE-to-HIGH certainty across the 200+ trial body with notable evidence for: antibiotic-associated diarrhoea prevention (BB-12 + LGG combination, Cochrane); paediatric acute gastroenteritis (Cochrane); functional constipation transit time (DN-173 010, HN019, Cheng 2021 PMID 34970580); elderly respiratory / immune function (HN019). Generic "bifidobacterium" (without strain identification) — INSUFFICIENT certainty for any specific clinical claim. UK NICE pathway inclusion — minimal (not specifically named in pathways despite the substantial trial body).
Known gaps
- Direct head-to-head trials across BB-12, HN019, and DN-173 010 at matched clinical indications.
- UK-specific RCTs of B. animalis lactis in UK populations + UK NHS-pathway contexts.
- Long-term safety data on sustained capsule supplementation (>1 year).
- Standardised UK consumer guidance on choosing strain by indication (currently scattered across brand marketing).
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
B. animalis lactis is well-tolerated. Severe immunocompromise: caution. Pregnancy / lactation: generally fine.
Talk to your pharmacist or GP first if you:
- You have severe immunocompromise (haematological malignancy, post-transplant, neutropaenic).
- You are taking antibiotics — separate dosing by 2-3 hours.
Common side effects: Mild GI upset on first introduction. Generally well-tolerated.
Pregnancy and breastfeeding
B. animalis lactis is widely consumed via yoghurt-fortified products (Activia, supermarket fermented dairy) in pregnancy without identified safety signals. Capsule supplementation with declared strain at standard dose (10⁹-10¹⁰ CFU/day) is generally fine in pregnancy — talk to your midwife if you are uncertain about a specific product or have a complex pregnancy.
As pregnancy — yoghurt-fortified and capsule B. animalis lactis are generally fine while breastfeeding without identified safety signals.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Severe immunocompromise (relative contraindication for live probiotics).
- Hypersensitivity to formulation constituents.
Drug interactions
Antibiotics (oral broad-spectrum: amoxicillin, doxycycline, ciprofloxacin, clindamycin, etc.) · low
Effect: Antibiotics kill bacteria — they do not distinguish between pathogens and probiotic strains in the gut. Co-administered probiotics need to be separated in time from each antibiotic dose to maximise probiotic survival. BB-12 + L. rhamnosus GG combination is Cochrane-evidenced for antibiotic- associated diarrhoea prevention when used this way.
Mechanism: Antibiotic disruption of normal gut flora is the underlying mechanism for antibiotic-associated diarrhoea. Probiotic co-administration helps maintain microbial diversity. Separating in time prevents direct antibiotic kill of the probiotic.
Action: Take probiotic 2-3 hours after each antibiotic dose. Continue probiotic for 1-2 weeks after completing the antibiotic course. Tell your prescriber or pharmacist if you want to add a probiotic during an antibiotic course.
Source: BNF probiotics + antibiotics; UK NICE CKS Diarrhoea (adults) + Gastroenteritis
Immunosuppressants (ciclosporin, tacrolimus, biologic DMARDs) in severe immunocompromise — relative contraindication for live probiotics; rare bacteraemia case reports. Disclose use to clinical team.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI bloating / soft stools on first introduction.
Rare side effects
- Bacteraemia / probiotic infection in severe immunocompromise (very rare; relative contraindication).
- Allergic reactions to yoghurt-substrate (milk-protein allergy).
How to take it
- Typical supplemental range
- Yoghurt-fortified: 100-200 g/day. Capsule: 10⁹-10¹⁰ CFU/day. Trial-evidence dose for AAD prevention (BB-12 + LGG combination): 10⁹-10¹⁰ CFU each strain, twice daily during antibiotic course + 1-2 weeks after.
- Timing
- Daily; with or without food. For antibiotic-associated diarrhoea prevention: separate by 2-3 hours from each antibiotic dose.
How to spot quality
Look for
- Specific strain identification: BB-12, HN019, DN-173 010 (or strain-deposit identifier — DSM, ATCC, CNCM).
- CFU count declared (typically 10⁹-10¹⁰ CFU/serving for capsule).
- Refrigeration declared if required (some live-culture products).
- Best-before / use-by date — live cultures decline over time.
- GMP-certified manufacture.
Red flags
- No strain identification — generic "bifidobacterium" carries no specific clinical claim.
- No CFU count.
- Marketing as a clinical-grade IBS or constipation remedy — UK NICE pathways use established interventions.
- Marketing for cancer treatment / cancer immunotherapy — outside trial-evidence boundaries.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Lactobacillus rhamnosus
Moderate evidenceBB-12 + L. rhamnosus GG — the most-evidenced probiotic combination for antibiotic-associated diarrhoea prevention.
BB-12 + LGG combination is supported by Cochrane systematic review for AAD prevention. Mechanism: complementary genus coverage (Bifidobacterium + Lactobacillus); BB-12 adheres to gut mucin; LGG supports gut-barrier integrity.
Evidence: Cochrane review supports BB-12 + LGG combination for AAD prevention. [3]
Doses studied: BB-12 10⁹-10¹⁰ CFU/day + LGG 10⁹-10¹⁰ CFU/day, alongside antibiotic course + 1-2 weeks after.
Bifidobacterium longum
Limited evidenceSister species combination — broad bifidobacterium coverage across the two human-resident species.
B. longum dominant in adult gut; B. animalis lactis dominant in commercial products. Combination extends bifidobacterium genus coverage. Mechanism complementary on Bifidobacterium-enrichment axis.
Evidence: Each component has individual trial body; combination trials small.
Doses studied: B. longum 10⁹-10¹⁰ CFU + B. animalis lactis 10⁹-10¹⁰ CFU/day capsule combination or multi-strain product.
Saccharomyces boulardii
Moderate evidenceAAD prevention cluster — both have AAD-prevention evidence via different mechanisms (live yeast vs lactic-acid bacterium).
S. boulardii antibiotic-resistance (yeast) + B. animalis lactis Bifidobacterium delivery — mechanism-complementary across two organism domains. Both are AAD-prevention evidence-supported.
Evidence: Each has individual AAD-prevention trial body; combination not directly trialled head-to-head. [3]
Doses studied: S. boulardii 250-1000 mg/day + B. animalis BB-12 10⁹-10¹⁰ CFU/day during antibiotic course.
Kefir (Multi-strain fermented milk)
Limited evidenceMulti-strain microbiome support — kefir is bifidobacterium-poor; B. animalis adds the genus.
Kefir delivers diverse Lactobacillus + yeast biomass; B. animalis adds bifidobacterium. Mechanism-complementary on microbial-diversity axis.
Evidence: Each component has individual trial body; combination not directly trialled.
Doses studied: Kefir 100-300 mL/day + B. animalis yoghurt or capsule 10⁹-10¹⁰ CFU.
Akkermansia muciniphila (next-generation probiotic)
Limited evidenceEstablished + next-generation probiotic combination — multi-strain microbiome support across different mechanism axes.
B. animalis lactis (carbohydrate-fermenting + SCFA + transit-time + immune); Akkermansia (mucus-layer + TLR2 + metabolic-syndrome). Different mechanisms; complementary axes.
Evidence: Different mechanisms; combination not directly trialled.
Doses studied: B. animalis lactis 10⁹-10¹⁰ CFU + pasteurised Akkermansia 10⁹-10¹⁰ CFU/day.
Kombucha (Fermented sweetened tea)
Limited evidenceKombucha is bifidobacterium-poor; combination with B. animalis extends bifidobacterium coverage.
Kombucha delivers Acetobacter + yeast biomass; B. animalis adds bifidobacterium genus.
Evidence: Each component has individual trial body; combination not directly trialled.
Doses studied: Kombucha 100-300 mL + B. animalis yoghurt or capsule daily.
Lactobacillus plantarum / Lactiplantibacillus plantarum (299v / CECT 7484/7485)
Limited evidenceMulti-strain cluster — most-trialled bifidobacterium combined with most-trialled L. plantarum strain.
Different genera; complementary niche. Multi-strain products extend coverage.
Evidence: Multi-strain microbiome support.
Doses studied: 10⁹-10¹⁰ CFU each daily.
Verifera™ editorial perspective
Why it matters. B. animalis lactis (especially the BB-12, HN019, DN-173 010 strains) is one of the best-evidenced probiotic strains globally — but consumer marketing frequently obscures the strain-specificity requirement, selling generic "bifidobacterium" products that may NOT contain the trial-evidenced strain. The Verifera editorial position is to keep strain identification front-and-centre and honestly surface the modest UK NICE pathway inclusion (yoghurt fortification is part of NHS-aligned dietary patterns; specific clinical indications use established medications).
Where Camden lands. Camden Medicals does NOT currently retail single-active B. animalis lactis capsule supplements. The entry serves as the bifidobacterium cluster reference alongside Camden's existing bifidobacterium-longum and the next-generation akkermansia-muciniphila entries. For UK consumers researching this space: identify the strain (BB-12 / HN019 / DN-173 010) and the CFU dose; for AAD prevention BB-12 + L. rhamnosus GG combination is Cochrane-evidenced; for transit-time improvement DN-173 010 (Activia) or HN019 (Optibac) have RCT evidence. Yoghurt-fortified delivery is fine for general microbiome support.
If you want to explore further. For general gut-health support: Activia or supermarket yoghurts with declared B. animalis lactis content. For antibiotic-associated diarrhoea prevention: BB-12 + L. rhamnosus GG combination capsule starting at the same time as antibiotics, continuing 1-2 weeks after completion. For functional constipation: DN-173 010 (Activia) or HN019 (Optibac) RCT-evidenced. Talk to your GP if you have diagnosed IBS, IBD, or chronic constipation — UK NICE pathway interventions come first, B. animalis lactis is an adjunct conversation.
How this entry was researched
Authoritative sources consulted:
- NHS Eatwell Guide + Pregnancy: vitamins, supplements and nutrition
- NICE CKS Constipation + Diarrhoea (adults) + Gastroenteritis + Irritable bowel syndrome
- Cochrane Database — probiotics for AAD + paediatric AGE
- GB Nutrition and Health Claims (NHC) Register (no authorised B. animalis lactis claim; brand-specific DN-173 010 Activia under EU Reg 432/2012)
- EFSA Article 13 generic-probiotic claims (on hold)
- Verifera bifidobacterium-longum + lactobacillus-rhamnosus + akkermansia-muciniphila entries (strain-specific cross-references)
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
Bifidobacterium animalis HN019 immune function elderly bowel
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.